Cover Image

Immunohistochemical profiling of liver metastases and matched-pair analysis in patients with metastatic pancreatic ductal adenocarcinoma

Show other versions (1)

Background - The purpose of the current study was to investigate the immunohistochemical (IHC) profile of liver metastases (LM) in patients with pancreatic ductal adenocarcinoma (PDAC). - Methods - Expression of 15 IHC markers in liver biopsies from 77 patients with PDAC, who were diagnosed between...

Full description

Saved in:
Bibliographic Details
Main Authors: Held, Thomas (Author) , Verbeke, Caroline S. (Author) , Strobel, Oliver (Author) , Rutkowski, Wiktor (Author) , Villard, Christina (Author) , Moro, Carlos Fernández (Author) , Del Chiaro, Marco (Author) , Büchler, Markus W. (Author) , Heuchel, Rainer (Author) , Löhr, J.-Matthias (Author)
Format: Article (Journal)
Language:English
Published: 14 September 2019
In: Pancreatology
Year: 2019, Volume: 19, Issue: 7, Pages: 963-970
ISSN:1424-3911
DOI:10.1016/j.pan.2019.09.005
Online Access:Verlag, Volltext: https://doi.org/10.1016/j.pan.2019.09.005
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1424390319307264
Get full text
Author Notes:Thomas Held, Caroline S. Verbeke, Oliver Strobel, Wiktor Rutkowski, Christina Villard, Carlos Fernández Moro, Marco Del Chiaro, Markus Büchler, Rainer Heuchel, Matthias Löhr
Description
Summary:Background - The purpose of the current study was to investigate the immunohistochemical (IHC) profile of liver metastases (LM) in patients with pancreatic ductal adenocarcinoma (PDAC). - Methods - Expression of 15 IHC markers in liver biopsies from 77 patients with PDAC, who were diagnosed between 2010 and 2014, were evaluated. In a separate subgroup analysis (n=12), paired samples (LM and primary tumor) from the same patient were investigated for IHC profile differences. - Results - LM samples were classified as pancreatobiliary-type (PB-type) in 72 patients (93.5%), intestinal-type (INT-type) in four patients (5.2%), and squamous in one patient (1.3%). There was no significant difference in overall survival (OS) between LM of the PB-type or INT-type (p=0.097). In a multivariate analysis, age <70 years (p=0.047), absence of SMAD4 mutation (p=0.026), absence of CDX2 expression (p=0.003), and well to moderate differentiation were significant prognostic factors for better OS in patients with LM (p=0.031). Analysis of paired tissue samples from LM and the primary tumor revealed a difference in CDX2 (50% increase, p=0.125) and SMAD4 (33% loss of SMAD4, p=0.375). - Conclusions - CDX2 expression and SMAD4 mutation indicate a poor outcome in patients with LM of PDAC. Matched-pair analysis revealed differences in distinct IHC marker expression.
Item Description:Gesehen am 05.12.2019
Physical Description:Online Resource
ISSN:1424-3911
DOI:10.1016/j.pan.2019.09.005

Similar Items